KOSDAQCosmetics406820

Beautyskin

₩1,541▲ 1.52%2026-11-18 close
Market Cap
₩21.8B
Turnover
₩72,239,695
Volume
50K
Shares out.
14.1M
PER
—
PBR
0.9×
EPS
-₩298
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Recover, but Losses Persist for Three Quarters

Beautyskin's sales rebounded to KRW 17.5 billion in the second quarter of 2026 with a small operating profit, but the company swung back to an operating loss of KRW 1.73 billion in the third quarter. Whether the sales recovery carries through to profit is the next point to watch.

  1. 1

    Annual sales went from KRW 80.9 billion in 2023 to KRW 80.9 billion in 2024 (no change year on year) and KRW 54.9 billion in 2025 (down 32.1% year on year). Of the 2022 to 2025 period, 2023 was the largest year.

  2. 2

    The company has posted an operating loss for three consecutive years from 2023 to 2025, with a 2025 operating loss of KRW 3.16 billion and an operating margin of -5.8%.

  3. 3

    The company recorded a net loss attributable to controlling shareholders in each of the three quarters from the first quarter to the third quarter of 2026, and the total for the most recent four quarters was KRW 426 million in losses attributable to controlling shareholders.

  4. 4

    The debt ratio rose from 99.4% in 2022 to 168.8% in 2025, and at the end of 2025 total equity stood at KRW 32.6 billion against total liabilities of KRW 55.1 billion.

  5. 5

    Press reports say the company has expanded investments outside its core cosmetics business, while it pursues a merger with a subsidiary and a Chinese hygiene permit for a brand product. The results of this restructuring have not yet appeared in reported earnings.

02

Business structure

Beautyskin is a cosmetics OEM/ODM and brand distribution specialist founded in 2011. It merged with JS Global in 2021, entered brand and product distribution through its Wonjin brand, and listed on KOSDAQ in July 2023.

According to a pre-listing securities report, the 2022 revenue mix was product distribution at 36.0%, OEM/ODM at 34.4%, and brands (Wonjin and URIID) at 29.5%.

A job-listing platform's profile as of March 2026 shows a mix of OEM/ODM at 44%, health supplements at 32%, product distribution at 12%, food processing at 7%, and other at 5%, although segment definitions differ across sources, so comparisons across dates are limited.

Its sales channels center on H&B stores and online platforms. Growth in these channels has opened opportunities for mid- to low-priced brands, but media have also flagged that intensifying competition could compress distribution margins if brand strength weakens.

The largest shareholder is CEO Kim Jong-soo, who held 43.25% at the end of 2026 per the latest filing.

Press reports in January 2026 said the company became the largest shareholder of a seafood distributor after acquiring a 54.55% stake, and that it converted convertible bonds of an insect-farming company into common shares, bringing that company in as an affiliate.

A company official reportedly acknowledged that the expansion is unrelated to the core business. As of 2026, the company has five consolidated subsidiaries.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.5B₩100M1.1%
2025Q4₩10.2B-₩800M−7.6%
2026Q1₩12.5B-₩1.5B−11.9%
2026Q2₩17.5B₩400M2.4%
2026Q3₩16.3B-₩1.7B−10.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩58.9B₩4B₩3.4B6.9%10.3%99.4%
2023₩80.9B-₩6.1B-₩8.6B−7.5%−24.6%111.5%
2024₩80.9B-₩1.2B-₩5.1B−1.5%−14.8%137.5%
2025₩54.9B-₩3.2B-₩1.7B−5.8%−5.4%168.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales rose from KRW 58.9 billion in 2022 to KRW 80.9 billion in 2023 (up 37.3% year on year), the high point of the period. Sales were unchanged at KRW 80.9 billion in 2024 and fell to KRW 54.9 billion in 2025 (down 32.1% year on year), the smallest year of the 2022 to 2025 period.

Operating profit of KRW 4.05 billion in 2022 turned into an operating loss of KRW 6.08 billion in 2023, followed by an operating loss of KRW 1.21 billion in 2024 (losses narrowed) and KRW 3.16 billion in 2025 (losses widened).

The operating margin moved from 6.9% in 2022 to -7.5% in 2023, -1.5% in 2024, and -5.8% in 2025. Net income attributable to controlling shareholders swung from KRW 3.36 billion in 2022 to a net loss of KRW 8.64 billion in 2023, then narrowed to net losses of KRW 5.06 billion in 2024 and KRW 1.73 billion in 2025.

Net loss including non-controlling interests was KRW 2.15 billion in 2025. For 2025, the company said that lower product sales reduced revenue, while higher fair value gains on financial assets measured at fair value through profit or loss improved net income.

The 2025 improvement at the net level therefore appears tied more to those valuation gains than to a recovery in operating earnings. Operating cash flow was KRW 3.09 billion in 2022, negative KRW 18.3 billion in 2023, KRW 8.89 billion in 2024, and KRW 610 million in 2025.

Quarterly, the third quarter of 2025 showed sales of KRW 11.5 billion and operating profit of KRW 123 million, while the fourth quarter showed sales of KRW 10.2 billion (down 10.7% from the prior quarter) and an operating loss of KRW 779 million.

The first quarter of 2026 showed sales of KRW 12.5 billion (up 22.4% from the prior quarter) with an operating loss of KRW 1.48 billion. The second quarter of 2026 showed sales of KRW 17.5 billion (up 39.6% from the prior quarter) and an operating profit of KRW 413 million.

The third quarter of 2026 showed sales of KRW 16.3 billion (down 6.4% from the prior quarter, up 42.7% year on year) and an operating loss of KRW 1.73 billion, a swing back into loss year on year.

05

Industry analysis

Beautyskin's industry backdrop is shaped by two forces: slowing Chinese demand and intensifying competition in domestic channels. In its first-quarter 2026 earnings commentary, a corporate data provider said intensifying competition in the global cosmetics market and slower growth in China weighed on results.

The same commentary noted that gross margin improved even as sales fell, and that cost restructuring helped defend profitability to some extent.

In domestic channels, growth at H&B stores and online platforms has opened room for mid- to low-priced brands, while the same sources warn that distribution margins could shrink if brand strength weakens under heavier competition.

In cycle terms, sales peaked in 2023 and declined through 2025, and quarterly sales showed signs of recovery in 2026 without yet covering operating costs.

In competitive terms, the OEM/ODM business overlaps with large contract manufacturers such as Cosmax and Kolmar Korea, while the brand and distribution business overlaps with brand owners such as Amorepacific and LG H&H in consumer channels.

Relative to these larger players, Beautyskin's scale and brand base are narrower, and the company's production-facility-led margin program is an attempt to change its cost structure within that landscape.

06

Outlook

Based on filings and press coverage, the company's stated direction comes down to three points. First, it is pursuing higher profitability through its production facilities. Second, it plans to merge with its subsidiary Wonjin W&Lab.

Third, it is proceeding with the registration process for a Chinese hygiene permit for Wonjin brand products. The first-quarter 2026 earnings commentary cited an improvement in gross margin as a positive sign.

At the same time, the swing to an operating profit in the second quarter of 2026 followed by a return to an operating loss in the third quarter makes it hard to judge the trend from quarterly figures alone.

A bonus share issue was disclosed on January 8, 2026, adding 10,602,117 common shares and increasing paid-in capital, so per-share comparisons are not on the same basis as before.

Export expansion in China depends on completing the Wonjin brand's hygiene permit registration, and the timing and outcome of that process have not been confirmed in a public schedule. The profit contribution from affiliate investments is also an item to check in the 2026 annual report.

The most direct checkpoint is whether the annual operating margin and operating loss in the 2026 annual report continue the trend of recent years.

07

Valuation

PER
—
PBR
0.9×
ROE
-15.8%
EPS
-₩298
BPS
₩1,802
Dividend per share
₩0

Valuation is more factually read against assets than against earnings. Because the net loss attributable to controlling shareholders over the most recent four quarters totals KRW 426 million, a price-to-earnings ratio cannot be calculated.

The price-to-book ratio sits below 1x, meaning the stock trades below its book value.

The quality of that book value, however, has to be viewed alongside the debt load: total liabilities of KRW 55.1 billion at the end of 2025 exceed total equity of KRW 32.6 billion, and equity attributable to controlling shareholders was KRW 32.2 billion.

The rise in the debt ratio from 99.4% in 2022 to 168.8% in 2025 also helps explain the discount to book. The dividend yield is below the industry average.

Earnings-based comparisons are hard to use because losses have persisted since 2023, and the last profitable year in the period, 2022, had an operating margin of 6.9%. Whether earnings recover is therefore the starting point for any valuation comparison.

The 2026 bonus share issue increased the share count, so per-share metrics need to be compared carefully against earlier periods.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sales recovery

Sales were KRW 12.5 billion in the first quarter of 2026 and rose to KRW 17.5 billion in the second quarter, up 39.6% from the prior quarter. The second quarter also brought a swing to an operating profit of KRW 413 million.

Third-quarter sales of KRW 16.3 billion were up 42.7% year on year, keeping revenue above the level of the third quarter of 2025. If the sales recovery persists, it can spread the burden of fixed costs across a larger base.

Gross margin and cost structure

A corporate data provider noted in its first-quarter 2026 commentary that gross margin improved even as sales declined. The same source said cost structure improvements helped defend profitability to some extent. The company has also stated that it aims to improve profitability through its production facilities.

If gains at the gross margin level are confirmed, they could become a starting point for recovering the operating margin.

China registration progress

The company has said it is proceeding with the registration of a Chinese hygiene permit for Wonjin brand products. Because China has been a major market for the company's sales expansion, completing the permit could widen sales channels for its brand products.

The completion timing has not been set out in any public schedule. Progress in this process is the benchmark for whether the China-related positive case strengthens.

09

Bear factors

Persistent operating losses

The company has posted operating losses for three consecutive years from 2023 to 2025, and the 2025 operating loss widened to KRW 3.16 billion. The third quarter of 2026 showed an operating loss of KRW 1.73 billion, a swing into loss year on year.

Net losses attributable to controlling shareholders were recorded in each of the three quarters from the first quarter to the third quarter of 2026. Isolated profitable quarters have not yet shown continuity, which is the main bearish point.

Rising financial burden

The debt ratio climbed from 99.4% in 2022 to 111.5% in 2023, 137.5% in 2024, and 168.8% in 2025. Total liabilities of KRW 55.1 billion at the end of 2025 exceed total equity of KRW 32.6 billion. Operating cash flow was negative KRW 18.3 billion in 2023 and only KRW 610 million in 2025. If borrowing capacity and cash generation weaken, the cost of funding the restructuring could rise.

Concerns over investments outside the core business

A January 2026 press report said the company kept investing in several businesses, including seafood distribution, insect farming, tea-leaf distribution, and health supplement distribution.

The report said these investments raised shareholder concerns while the core cosmetics business's sales and profitability deteriorated. A company official was reported to have acknowledged that the expansion is unrelated to the core business.

If the returns from these investments do not appear in reported earnings, questions over capital allocation may persist.

10

Risk factors

Financial and liquidity

With the debt ratio at 168.8% at the end of 2025, a change in interest rates or borrowing terms could weigh on earnings through financing costs. Operating cash flow of KRW 610 million in 2025 points to limited cash generation. If losses continue, additional funding may be needed, which could weaken the capital structure further.

China demand and channel competition

A corporate data provider noted that intensifying global cosmetics competition and slower growth in China weighed on first-quarter 2026 results. Concerns have also been raised that distribution margins could fall if competition in H&B and online channels intensifies.

Because sales declined from 2025 onward, demand volatility tied to channel structure changes is a significant risk.

Execution of restructuring

The planned merger with the subsidiary Wonjin W&Lab and the Chinese hygiene permit for Wonjin brand products have not been completed. If the scope of investments widens before the profit contribution of affiliates is confirmed, the financial burden could grow.

With the largest shareholder holding 43.25%, a change in management direction would also shape decision-making, which is relevant to minority shareholders.

11

What to watch next

  1. Around mid-March 2027

    Preliminary full-year 2026 results. The 2025 preliminary results were disclosed on March 12, 2026. The key points are whether the operating loss extends for a fourth year and whether the operating margin improves from -5.8% in 2025.

  2. Late March 2027

    Filing deadline for the 2026 annual report. Full-year operating results, the debt ratio, operating cash flow, and profit contributions from affiliate investments will be confirmed in the periodic report.

  3. March 2027 (annual general meeting)

    The annual general meeting. The March 27, 2026 meeting approved financial statements and the re-election of an executive director. Results on financial statement approval and any board changes will be checked.

  4. Mid-May 2027

    First-quarter 2027 earnings release. First-quarter 2026 results were announced on May 15, 2026. The main point is whether the second-quarter 2026 profit was a one-off or whether profitable quarters continue.

  5. After December 2026 (timing not set)

    Progress on the merger with the subsidiary Wonjin W&Lab and completion of the Chinese hygiene permit registration for Wonjin brand products. When filings appear, the merger terms and whether China export resumes will be checked.

12

Overall view

Beautyskin's sales declined from a peak of KRW 80.9 billion in 2023 to KRW 54.9 billion in 2025, the smallest year of the 2022 to 2025 period.

The company has posted operating losses for three consecutive years from 2023 to 2025, and according to the company's own explanation, the narrower net loss in 2025 was influenced by valuation gains on financial assets.

Sales recovered to KRW 17.5 billion in the second quarter of 2026, and that quarter also brought an operating profit, but the third quarter returned to an operating loss of KRW 1.73 billion. The net loss attributable to controlling shareholders over the most recent four quarters totals KRW 426 million.

On the financial side, the debt ratio rose from 99.4% in 2022 to 168.8% in 2025, and the price-to-book ratio below 1x appears to reflect both this financial burden and weak earnings.

Positive factors include the sales recovery, the gross margin improvement, and progress on the Chinese hygiene permit, while negative factors include persistent operating losses, the debt load, and uncertain returns from investments outside the core business.

The next points to confirm are the preliminary full-year 2026 results around mid-March 2027 and the operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. comp.wisereport.co.kr
  4. kr.investing.com
  5. kr.investing.com
  6. m.news.nate.com
  7. eugenefn.com
  8. news.nate.com
  9. investing.com
  10. jobkorea.co.kr
  11. thenext-news.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis